What is the appropriate management of ketamine-induced arrhythmias?

Management of Ketamine-Induced Arrhythmias

Immediately discontinue ketamine and provide supportive cardiovascular management with continuous cardiac monitoring, as ketamine causes sympathomimetic-mediated tachyarrhythmias through catecholamine reuptake inhibition.

Immediate Actions

1. Stop Ketamine Administration

• Discontinue ketamine infusion or avoid additional boluses immediately upon arrhythmia detection
• The FDA label confirms ketamine increases blood pressure, heart rate, and cardiac output through indirect sympathomimetic activity by inhibiting central and peripheral catecholamine reuptake 1

2. Hemodynamic Assessment and Monitoring

Assess the patient's hemodynamic stability first:

• If hemodynamically unstable (systolic BP ≤90 mmHg, chest pain, heart failure, rate ≥150 bpm):

  • Prepare for synchronized cardioversion per standard ACLS protocols 2
  • Establish IV access if not already present
  • Administer oxygen and ensure adequate ventilation 2

• If hemodynamically stable:

  • Continue continuous cardiac monitoring
  • Obtain 12-lead ECG to characterize the arrhythmia

Specific Arrhythmia Management

For Ventricular Tachycardia (VT)

Wide-complex tachycardia should be presumed VT if diagnosis is unclear 3

Hemodynamically stable VT:

• First-line: Intravenous procainamide (useful to terminate VT) 3
• Alternative: Intravenous lidocaine 50 mg over 2 minutes, repeat every 5 minutes to total dose of 200 mg, then start infusion 2-4 mg/min 2
• Amiodarone or sotalol may be considered as second-line agents 3

Hemodynamically unstable VT:

• Sedate patient if conscious
• Synchronized DC cardioversion: 100 J → 200 J → 360 J 2

For Supraventricular Tachycardia (SVT)

If hemodynamically stable:

• Attempt vagal maneuvers first (Valsalva maneuver, carotid massage if no bruit) 2
• Adenosine 3 mg rapid IV bolus followed by saline flush; if no effect after 1-2 minutes, give 6 mg, then 12 mg maximum 2
  • Contraindicated in asthmatics (risk of bronchospasm)
  • Must be given in monitored environment
• Alternative: Verapamil 5-10 mg IV over 60 seconds (contraindicated if patient on beta-blockers) 2

If hemodynamically unstable:

• Sedate and perform synchronized cardioversion 2

For Ventricular Fibrillation (VF)

• Immediate defibrillation takes priority over pharmacotherapy 2
• Follow standard ACLS protocols
• Consider intravenous lidocaine for witnessed cardiac arrest due to VF unresponsive to CPR, defibrillation, and vasopressor therapy 3

Pharmacological Adjuncts for Ketamine-Specific Arrhythmias

Beta-Blocker Administration

Metoprolol is specifically protective against ketamine-induced arrhythmias:

• Research demonstrates metoprolol prevents ketamine-induced ventricular structural remodeling, sympathetic sprouting, and increased susceptibility to ventricular arrhythmias 4
• Dose: Metoprolol 20 mg/kg/day orally (based on animal studies showing efficacy)
• Particularly useful for polymorphic VT due to sympathetic surge 3
• Intravenous beta-blockers are useful for polymorphic VT due to myocardial ischemia and for VT/VF storm 3

Avoid Prophylactic Antiarrhythmics

• Do not give prophylactic lidocaine or high-dose amiodarone - this is potentially harmful 3

Monitoring and Supportive Care

Cardiovascular Monitoring

• Continuous telemetry monitoring
• Serial vital signs (BP typically returns to baseline within 15 minutes after ketamine) 1
• Monitor for respiratory depression with overdosage or rapid administration 1
• Assisted ventilation may be required in overdose situations 1

Electrolyte Management

• Check and correct electrolyte abnormalities, particularly:
  • Potassium (hypokalemia increases arrhythmia risk)
  • Magnesium (consider 8 mmol bolus for VF/VT, especially with acute MI) 2

Special Considerations

Duration of Effects

• Ketamine's redistribution half-life from CNS is 2.5 hours 1
• Initial alpha phase lasts approximately 45 minutes with half-life of 10-15 minutes 1
• Most cardiovascular effects resolve within 15 minutes 1

Chronic Ketamine Use

• Long-term ketamine abuse causes ventricular myocardial apoptosis, fibrosis, and sympathetic sprouting, increasing susceptibility to malignant arrhythmias 4
• Can lead to acute systolic heart failure with severely reduced ejection fraction 5
• Screen for ketamine use disorder in young adults with unexplained acute heart failure 5

Common Pitfalls to Avoid

1. Do not assume wide-complex tachycardia is SVT with aberrancy - treat as VT until proven otherwise 3
2. Do not use verapamil in patients on beta-blockers - risk of profound bradycardia and hypotension 2
3. Do not give high-dose epinephrine (>1 mg boluses) in cardiac arrest - not beneficial 3
4. Do not give magnesium for refractory VF not related to torsades de pointes - not beneficial 3
5. Avoid adenosine in asthmatic patients - can precipitate bronchospasm 2
6. Do not continue ketamine infusion once arrhythmia is identified - the sympathomimetic effects perpetuate the arrhythmia 1